Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter?
Open Access
- 19 March 2019
- journal article
- research article
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 19 (1) , 1-10
Abstract
Differences in adherence may represent drug properties (e.g. dosing interval) or patient experiences while on treatment. Adherence to direct oral anticoagulants (DOACs) in nonvalvular atrial fibrillation (NVAF) is important to maintain effectiveness over the course of treatment. This was a retrospective cohort study using 2009–2015 Truven Health MarketScan Databases. New initiators of dabigatran, rivaroxaban, and apixaban with NVAF were identified. Twelve months of continuous enrollment before treatment was required to assess demographics and medical history. Proportion of days cover (PDC) was used to measure adherence at 3, 6, 9 and 12-month. Gaps in therapy and treatment switches were also evaluated. Logistic regression was used to compare high adherence (PDC ≥0.80). A total of 14,864 dabigatran, 16,005 rivaroxaban, and 8078 apixaban users were identified. Apixaban users had the highest adherence overall, with mean PDC at 3, 6, 9, and 12-months of 0.83, 0.76, 0.72, and 0.69, while dabigatran had the lowest adherence of 0.78, 0.67, 0.61, and 0.57. Adherence to DOACs increased with increased stroke risk scores. Adherence was also higher when first days supplied was > 30 days compared to 30 days and when filled via mail order pharmacies. Switching was highest among dabigatran users. Apixaban users were the most likely to have high adherence versus dabigatran (OR = 1.73, 95% CI = 1.60–1.88) and versus rivaroxaban (OR = 1.24, 95% CI = 1.14–1.34) at 12-months. Apixaban users had the highest overall adherence despite twice-daily dosing versus once-daily dosing for rivaroxaban. These findings can be useful for formulary decision-making and when assessing treatment options.Keywords
Funding Information
- Pharmaceutical Research and Manufacturers of America Foundation (Research Starter Grant)
This publication has 40 references indexed in Scilit:
- From monitoring to vigilance about patient adherence to new oral anticoagulantsEP Europace, 2013
- Drug adherence in patients taking oral anticoagulation therapyClinical Research in Cardiology, 2013
- Association Between Medicare Advantage Plan Star Ratings and EnrollmentJAMA, 2013
- Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous ThromboembolismAnnals of Internal Medicine, 2012
- Comparative Efficacy and Safety of New Oral Anticoagulants in Patients With Atrial FibrillationCirculation: Cardiovascular Quality and Outcomes, 2012
- Antithrombotic Therapy for Atrial FibrillationChest, 2012
- A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial FibrillationChest, 2010
- Refining Clinical Risk Stratification for Predicting Stroke and Thromboembolism in Atrial Fibrillation Using a Novel Risk Factor-Based ApproachChest, 2010
- A review of uses of health care utilization databases for epidemiologic research on therapeuticsJournal of Clinical Epidemiology, 2005
- Administrative data based patient safety research: a critical reviewQuality and Safety in Health Care, 2003